BCD-217

BIOLOGICAL3 trials

Sponsors

Biocad

Conditions

MelanomaMelanoma (Skin)Melanoma AdvancedMelanoma MetastaticMelanoma Stage IIIMelanoma Stage IVMelanoma Unresectable

Phase 2

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

BiocadMelanoma, Melanoma Metastatic

Start: 2019-07-01End: 2023-12-31Updated: 2023-02-10

Phase 3

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruitingNCT05732805

BiocadMelanoma, Melanoma Advanced, Melanoma Metastatic +4

Start: 2022-08-02End: 2025-07-31Target: 270Updated: 2025-02-27

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Active, not recruitingNCT05751928

BiocadMelanoma (Skin), Melanoma Stage III

Start: 2023-04-05End: 2027-06-30Updated: 2025-07-08

Related Papers

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.

2025-08-05

Efficacy and safety of first-line prolgolimab and nurulimab versus nivolumab and ipilimumab in advanced or metastatic melanoma: Indirect treatment comparison.

Journal of Clinical Oncology2025-05-281 citations

Abstract 653: Proved clinical benefit of low-dose anti-CTLA4 + anti-PD-1 immunotherapy versus mono anti-PD-1 therapy in patients unresectable or metastatic melanoma: Phase III OCTAVA trial

Cancer Research2025-04-213 citations

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

Frontiers in Oncology2024-09-041 citations

Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study

Journal of Modern Oncology2023-12-106 citations